CFA David Thomas

Mar 29, 2024 | bio.news | David Thomas |Samantha Sault |CFA David Thomas

A year ago, the sentiment for the industry was extremely low. In 2023, the biotech stock indices were sliding to potential new lows, levels not seen since 2017. Everything from venture capital to licensing was trending down significantly, and we were coming off the heels of the newly passed Inflation Reduction Act (IRA). It was hard to find positive signals to present at events such as BIO-Europe. But things have changed heading into 2024.